Novo Nordisk shares plunge 22% after CagriSema obesity drug trial results
December 20, 2024 at 06:28 AM EST
Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage trial that missed expectations.